首页> 外文期刊>Journal of Microencapsulation: Microcapsules Liposomes Nanoparticles Microcells Microspheres >Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasis
【24h】

Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasis

机译:基于壳聚糖的巨噬细胞介导的药物靶向治疗实验性内脏利什曼病

获取原文
获取原文并翻译 | 示例
           

摘要

The potential of chitosan microparticies as a carrier of doxorubicin for the treatment of visceral leishmaniasis was evaluated by macrophage-mediated drug targeting approach. Cationic charge of doxorubicin was masked by complexing it with dextran sulphate (a poly anion) in order to facilitate its incorporation into cationic chitosan microparticies. Prior to in vitro and in vivo studies, characterization studies were carried out systematically: particle size (~1.049 μm), surface morphology (fluorescence microscopy - spherical structured microparticies), Fourier transform infrared spectroscopy (to characterize effective cross-linking) and differential scanning calorimetry. In vitro studies were carried out in J774.1 in order to check the effective endocytotic uptake of microparticies by macrophages. In vivo studies were conducted in Syrian golden hamsters as per well-established protocols and the results drawn from in vivo studies displayed substantial reduction in leishmanial parasite load for doxorubicin-encapsulated chitosan microparticies: ~78.2 ± 10.4%, when compared to the control (free doxorubicin): 33.3 ± 2.4%.
机译:通过巨噬细胞介导的药物靶向方法评估了壳聚糖微粒作为阿霉素载体治疗内脏利什曼病的潜力。通过将阿霉素与硫酸葡聚糖(一种聚阴离子)复合来掩盖其阳离子电荷,以便于将其掺入阳离子壳聚糖微粒中。在进行体外和体内研究之前,系统地进行了表征研究:粒径(〜1.049μm),表面形态(荧光显微镜-球形结构微粒),傅里叶变换红外光谱(表征有效的交联)和差示扫描量热法。为了检查巨噬细胞对微粒的有效内吞摄取,在J774.1中进行了体外研究。按照公认的方案,在叙利亚金仓鼠中进行了体内研究,从体内研究中得出的结果表明,与对照相比,阿霉素包裹的壳聚糖微颗粒的利什曼原虫载量大大降低:〜78.2±10.4%(免费)阿霉素):33.3±2.4%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号